Company
Diopsys
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
0
510(k), De Novo and PMA
Device trials
0
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
Recall records
2
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$1.0M
1 Form D offering, 2019 to 2019
Equity
$0
Stock sold for cash
Debt and convertible notes
$1.0M
$1.0M of it convertible
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: convertible note, $1.0M raised of $1.0M sought, first sale Oct 17, 2019, 12 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Oct 17, 2019 | Convertible note | $1.0M | $1.0M | 12 | Rule 506(b) | Form D ↗Mar 24, 2020 |
Company details
From the company's latest Form D.
- Legal name
- DIOPSYS INC
- Headquarters
- Pine Brook, New Jersey
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1117673 ↗
Executives, directors and promoters
As listed on the latest Form D.
7 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Diopsys.
Latest FDA decisions
No 510(k), De Novo or PMA decisions under this name since 2015.
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
No device trials list this company as lead sponsor.
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1437-2010 · Started Apr 2, 2007 · Posted by FDA Apr 26, 2010
Reason given: The computer based system may lose test counts when the time in the device was changed during a changeover from standard time to daylight savings time in March 2007.
Cause as FDA categorized it: Software design · Device type: Stimulator, Photic, Evoked Response (GWE)
Z-0186-05 · Started Sep 15, 2004 · Posted by FDA Nov 6, 2004
Reason given: The firm established no medical device quality system, no established quality plan and no established quality procedures.
Cause as FDA categorized it: Other · Device type: Stimulator, Photic, Evoked Response (GWE)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.